SeaStar Medical Holding Corp Ordinary Shares ICU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
Trading Information
- Previous Close Price
- $1.92
- Day Range
- $1.89–1.96
- 52-Week Range
- $1.89–5.38
- Bid/Ask
- $1.92 / $1.98
- Shares Outstanding
- 5.32M
- Market Cap
- $10.21M
- Volume/Avg
- 10,412 / 158,816
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 17
Valuation
Metric | ICU |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.90 |
Price/Sales | 4.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ICU |
|---|---|
Quick Ratio | 1.65 |
Current Ratio | 1.89 |
Interest Coverage | −518.11 |
Quick Ratio
ICU
Profitability
Metric | ICU |
|---|---|
Return on Assets (Normalized) | −115.11% |
Return on Equity (Normalized) | −181.21% |
Return on Invested Capital (Normalized) | −180.28% |
Return on Assets
ICU
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<@k!%%& | LOCK|D%@^! | $138B | |||
| Moderna Inc MRNA | LOCK|p^jTR^Y | LOCK|h> | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!&QFhD | LOCK|DLs>$ | $93B | |||
| argenx SE ADR ARGX | LOCK|&Dn&^B | LOCK|FF | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|^&f!%^N | LOCK|?G! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|b@CtJKxg | LOCK|N$?F# | $30B | |||
| Incyte Corp INCY | LOCK|@$VT^b | LOCK|n$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|R!xr!Q^ | LOCK|>LK | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Nfx?L@ | LOCK|>!$! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|czJ?j^& | LOCK|>$P | $15B |
United States